Constipation Predominant Irritable Bowel Syndrome
7
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
57%
4 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
"Efficacy and Safety of Linaclotide in Chronic Constipation"
Soluble and Osmotic Fibre (SOLOS) Diet for Constipation
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)